Clinical trials: Ophthalmic Solutions, active
Dry Eye
A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease
This is a Phase 2 clinical study designed to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution compared with placebo in participants with dry eye disease. The study will enroll adults with dry eye disease.
- Trial name
- NCT07625124
- Testing
- RCI001 Ophthalmic Solution
- Volunteers
- 200 people
- Sponsor
- Rudacure
Dry Eye Disease (DED)
Efficacy and Safety of VMX Eye Drops for Dry Eye Disease
This multicenter, randomized, double-blind study evaluates the safety and effectiveness of VMX eye drops in patients with dry eye disease.
- Trial name
- NCT07369375
- Testing
- VMX Eye Drops
- Volunteers
- 76 people
- Sponsor
- VISUfarma SpA
Myopia
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
A randomized, double-blind, placebo-controlled, multicenter, phase III clinical study of the efficacy and safety of two low-concentration atropine sulfate eye drops in slowing the progression of myopia in children
- Trial name
- China-CHAMP (NCT06209320)
- Testing
- Lower dose atropine sulfate eye drops, Low dose atropine sulfate eye drops
- Where
- China
- Volunteers
- 777 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Epiphora
Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)
This study tests whether a very low concentration of atropine eye drops (0.005%) reduces excessive tearing (epiphora) in adults.
- Trial name
- NCT07816224
- Testing
- Atropine sulfate ophthalmic solution 0.005%, Vehicle arm
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rehan Ahmed
Dry Eye
A Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease
A Double-Masked, Randomized, Parallel Group, Non-Inferiority Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease
- Trial name
- NCT07593885
- Testing
- Artelac® Complete MDO® Eye Drops, VISMED® MULTI Eye Drops
- Where
- 12 sites in Germany
- Volunteers
- 160 people
- Sponsor
- Dr. Gerhard Mann chem.-pharm. Fabrik GmbH
Fuchs Endothelial Corneal Dystrophy
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
- Trial name
- NCT04440280
- Testing
- N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Dry Eye Syndromes, Computer Vision Syndrome
Protecting the Eyes of Gamers With Lubricating Eyedrops
The excessive use of screens particularly amongst digital gamers can adversely impact the health of the surface of the eyes with symptoms and signs of surface damage.
- Trial name
- PROTEGE (NCT06163989)
- Testing
- TheaLoz Duo Eyedrop
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- Aston University
Atopic Keratoconjunctivitis
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC.
- Trial name
- NCT07395232
- Testing
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Where
- 19 sites in United States, Italy and 1 more
- Volunteers
- 153 people
- Sponsor
- Dompé Farmaceutici S.p.A
Keratoconus
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
- Trial name
- NCT07400952
- Testing
- GLK-221 Ophthalmic Solution
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Glaukos Corporation
Geographic Atrophy of the Macula
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina.
- Trial name
- eDREAM (NCT06659549)
- Testing
- GAL-101
- Where
- 24 sites in United States, Armenia and 6 more
- Volunteers
- 110 people
- Sponsor
- Galimedix Therapeutics Inc
Myopia
Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine
0.01% atropine is an effective measure for controlling myopia in children and is widely used in Asia for this purpose. However, there is a phenomenon of rebound and worsening of myopia after discontinuation of the medication.
- Trial name
- NCT07129889
- Testing
- gradual withdrawal of medication, Auricular acupressure
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Ningbo Eye Hospital
Dry Eye
JN002 for the Treatment of Dry Eye Disease
This is a first-in-human, single-center, randomized, double-blind, placebo-controlled clinical trial designed to:·Evaluate the efficacy of JN002 Ophthalmic Solution in treating dry eye disease (DED)·Assess the safety of JN002…
- Trial name
- NCT07245017
- Testing
- JN002 Ophthalmic Solution (0.05 mg/mL), JN002 Ophthalmic Solution (0.1 mg/mL)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Dry Eye Disease (DED), Tear Break-Up Time
Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient With Moderate to Severe Dry Eye
This study aimed to evaluate the efficacy and safety of 0.28% preservative-free SH and 0.18% SH eye drops in patients with dry eye disease.
- Conditions
- Dry Eye Disease (DED), Tear Break-Up Time, Tear Disorder, Tear Film Insufficiency
- Trial name
- NCT06860659
- Testing
- 0.28% Sodium Hyaluronate , preservative free eye drops, 0.18% Sodium Hyaluronate , preservative free eye drops
- Where
- Thailand
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Neonatal Dacryocystitis, Congenital Nasolacrimal Duct Obstruction
Efficacy and Safety of Piclosept in the Complex Treatment of Neonatal Dacryocystitis
This single-center, prospective, randomized, controlled, assessor-blinded study will evaluate the efficacy and safety of Piclosept® ophthalmic solution as an adjunct to standardized lacrimal sac massage in children aged 1 to 12…
- Trial name
- NCT07875517
- Testing
- Picloxidine, Levofloxacin, Standardized lacrimal sac massage
- Where
- Kazakhstan
- Volunteers
- 90 people
- Sponsor
- Kazakh Eye Research Institute
Myopia
Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control
To evaluate the effectiveness and safety of DIMS, low concentration atropine eye drops,and atropine combined with DIMS in controlling axial length and refraction in children with moderate to high myopia.
- Trial name
- atropine (NCT06523504)
- Testing
- DIMS, The 0.02% ATP Group, The 0.04% ATP Group
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Ruihua Wei
Glaucoma, Ocular Hypertension
Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells
a randomized, investigator-blind, interventinal study will compare the effect of benzalkonium-chloride (BAK) preserved and preservative-free (PF) eye drops on conjunctival goblet cells.
- Trial name
- NCT04957329
- Testing
- Xalatan, Monoprost
- Where
- 2 sites in Denmark
- Volunteers
- 28 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cataract, Glaucoma
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension…
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Trial name
- NCT07218783
- Testing
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- SpyGlass Pharma, Inc.
Acquired Blepharophimosis
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
- Trial name
- NCT06514612
- Testing
- STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
- Where
- 36 sites in Czechia, France and 7 more
- Volunteers
- 234 people
- Sponsor
- Santen SAS
Meibomian Gland Dysfunction (MGD)
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes.
- Trial name
- NCT07224529
- Testing
- Vevye(Cyclosporine 0.1% Ophthalmic Solution)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Alabama at Birmingham
Dry Eye
The Effect of Cord Blood Serum Eyes Drops Administer in Patients With Severe Keratopathy Related to EGFR-I Treatment
The study aim to evaluate the efficacy of cord blood eye drops in the healing of the damaged corneal epithelium.
- Trial name
- NCT06830551
- Testing
- administration cord blood based eye drops, standardized to the deliver BDNF.
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna